Skip to Content

Zembrace SymTouch Approval History

  • FDA approved: Yes (First approved January 28th, 2016)
  • Brand name: Zembrace SymTouch
  • Generic name: sumatriptan
  • Dosage form: Injection
  • Company: Dr. Reddy's Laboratories, Inc.
  • Treatment for: Migraine

Zembrace SymTouch (sumatriptan) is a selective 5-HT1B/ID receptor agonist in a prefilled, ready-to-use, single-dose disposable autoinjector for the treatment of acute migraine episodes, with or without aura.

Development History and FDA Approval Process for Zembrace SymTouch

Jan 29, 2016Approval Dr. Reddy’s Laboratories Ltd. Receives FDA Approval for Zembrace SymTouch (sumatriptan succinate) Injection for the Acute Treatment of Migraines

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.